Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Fitchett · SciRah

Researcher profile · Semantic Scholar

D. Fitchett

Share profile

D. Fitchett — researcher profile on SciRah

h-index: 60
Works: 321
Citations: 23K

Most-cited papers

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
S. Inzucchi, B. Zinman, D. Fitchett, C. Wanner +9 more
2017Diabetes Care646 citations Open access
Semantic Scholar
Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
S. Verma, C. Mazer, Andrew T. Yan, T. Mason +15 more
2019Circulation448 citations Open access
Semantic Scholar
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
C. Wanner, J. Lachin, S. Inzucchi, D. Fitchett +6 more
2018Circulation386 citations Open access
Semantic Scholar
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
D. Fitchett, S. Inzucchi, C. Cannon, D. McGuire +7 more
2018Circulation298 citations Open access
Semantic Scholar
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
D. Fitchett, J. Butler, P. van de Borne, B. Zinman +7 more
2018European Heart Journal225 citations Open access
Semantic Scholar
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
N. Sattar, D. Fitchett, S. Hantel, J. George +1 more
2018Diabetologia169 citations Open access
Semantic Scholar
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
S. Verma, C. Mazer, M. Al-Omran, S. Inzucchi +4 more
2017Circulation148 citations Open access
Semantic Scholar
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
S. Inzucchi, M. Kosiborod, D. Fitchett, C. Wanner +4 more
2018Circulation146 citations Open access
Semantic Scholar
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Olivia R. Ghosh-Swaby, S. Goodman, Lawrence A Leiter, Alice Y. Y. Cheng +5 more
2020The Lancet Diabetes and Endocrinology118 citations
Semantic Scholar
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
P. Monteiro, R. Bergenstal, Elvira Toural, S. Inzucchi +6 more
2019Age and Ageing114 citations Open access
Semantic Scholar
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
S. Verma, C. Mazer, D. Fitchett, S. Inzucchi +3 more
2018Diabetologia112 citations Open access
Semantic Scholar
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
M. Böhm, J. Slawik, M. Brueckmann, M. Mattheus +9 more
2019European Journal of Heart Failure98 citations Open access
Semantic Scholar
A safety update on sodium glucose co‐transporter 2 inhibitors
D. Fitchett
2019Diabetes, obesity and metabolism88 citations
Semantic Scholar
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
S. Inzucchi, D. Fitchett, D. Jurišić-Eržen, V. Woo +5 more
2019Diabetes, obesity and metabolism68 citations
Semantic Scholar
Abstract 15893: Mediators of the Improvement in Heart Failure Outcomes With Empagliflozin in the EMPA-REG OUTCOME Trial
D. Fitchett, S. Inzucchi, B. Zinman, C. Wanner +9 more
201766 citations
Semantic Scholar
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
D. McGuire, B. Zinman, S. Inzucchi, C. Wanner +12 more
2020The Lancet Diabetes and Endocrinology64 citations
Semantic Scholar
Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
B. Zinman, S. Inzucchi, C. Wanner, U. Hehnke +4 more
2018Diabetologia62 citations Open access
Semantic Scholar
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
G. Savarese, N. Sattar, J. Januzzi, S. Verma +10 more
2019Circulation53 citations Open access
Semantic Scholar
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
S. Verma, Q. Ji, Deepak L. Bhatt, C. Mazer +8 more
2020Diabetes, obesity and metabolism43 citations Open access
Semantic Scholar
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
J. Butler, F. Zannad, D. Fitchett, B. Zinman +7 more
2019Circulation: Heart Failure43 citations
Semantic Scholar
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial
P. Pellicori, D. Fitchett, Mikhail N. Kosiborod, A. Ofstad +8 more
2021European Journal of Heart Failure38 citations Open access
Semantic Scholar
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
J. Ferreira, D. Fitchett, A. Ofstad, B. Kraus +7 more
2020American Journal of Hypertension38 citations Open access
Semantic Scholar
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
S. Inzucchi, K. Khunti, D. Fitchett, C. Wanner +4 more
2020Journal of Clinical Endocrinology and Metabolism38 citations Open access
Semantic Scholar
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.
S. Verma, C. Wanner, I. Zwiener, A. Ofstad +3 more
2019Journal of the American College of Cardiology37 citations Open access
Semantic Scholar
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
D. Fitchett, S. Inzucchi, J. Lachin, C. Wanner +7 more
2018Journal of the American College of Cardiology37 citations Open access
Semantic Scholar
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
D. Fitchett, S. Inzucchi, C. Wanner, M. Mattheus +4 more
2019European Heart Journal36 citations Open access
Semantic Scholar
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
B. Claggett, J. Lachin, S. Hantel, D. Fitchett +4 more
2018Circulation33 citations
Semantic Scholar
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
S. Verma, Abhinav K. Sharma, B. Zinman, A. Ofstad +8 more
2020Diabetes, obesity and metabolism30 citations Open access
Semantic Scholar
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
G. Savarese, A. Uijl, L. Lund, S. Anker +11 more
2021Journal of Cardiac Failure27 citations Open access
Semantic Scholar
Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus.
Abhinav K. Sharma, Lauren B. Cooper, M. Fiuzat, R. Mentz +6 more
2018JACC. Heart failure27 citations Open access
Semantic Scholar
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
S. Verma, C. Mazer, Deepak L. Bhatt, S. Raj +8 more
2019Diabetes Care24 citations
Semantic Scholar
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management.
G. B. John Mancini, Alice Y. Y. Cheng, K. Connelly, D. Fitchett +9 more
2017Canadian Journal of Cardiology24 citations
Semantic Scholar
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
J. Ferreira, S. Verma, D. Fitchett, A. Ofstad +6 more
2020Cardiovascular Diabetology22 citations Open access
Semantic Scholar
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
J. Januzzi, J. Ferreira, M. Böhm, S. Kaul +8 more
2019European Journal of Heart Failure22 citations
Semantic Scholar
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
M. Böhm, D. Fitchett, A. Ofstad, M. Brueckmann +9 more
2020Journal of Hypertension20 citations
Semantic Scholar
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
P. Pellicori, A. Ofstad, D. Fitchett, C. Zeller +5 more
2020ESC Heart Failure20 citations Open access
Semantic Scholar
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
M. Vaduganathan, S. Inzucchi, N. Sattar, D. Fitchett +8 more
2021Diabetes, obesity and metabolism18 citations Open access
Semantic Scholar
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Abhinav K. Sharma, A. Ofstad, Tariq Ahmad, B. Zinman +7 more
2021JACC. Heart failure18 citations Open access
Semantic Scholar
Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease
Abhinav Sharma, S. Inzucchi, J. Testani, A. Ofstad +6 more
2023ESC Heart Failure17 citations Open access
Semantic Scholar
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
S. Verma, Lawrence A Leiter, B. Zinman, Abhinav K. Sharma +7 more
2021ESC Heart Failure17 citations Open access
Semantic Scholar
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
J. Ferreira, B. Kraus, I. Zwiener, S. Lauer +7 more
2021Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease17 citations Open access
Semantic Scholar
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
R. Coleman, A. Gray, Uli C. Broedl, D. Fitchett +4 more
2020Diabetes, obesity and metabolism15 citations Open access
Semantic Scholar
Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice
D. Fitchett
2018European Endocrinology14 citations Open access
Semantic Scholar
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®
G. Langslet, B. Zinman, C. Wanner, S. Hantel +3 more
2020Diabetes & vascular disease research13 citations Open access
Semantic Scholar
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
S. Anker, L. Sander, D. Fitchett, B. Zinman +7 more
2022Diabetes Research and Clinical Practice12 citations Open access
Semantic Scholar
SGLT2 inhibitors in the real world: too good to be true?
D. Fitchett
2017The Lancet Diabetes and Endocrinology11 citations
Semantic Scholar
EMPAGLIFLOZIN (EMPA) REDUCES HEART FAILURE OUTCOMES IRRESPECTIVE OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C CONTROL
D. Fitchett, J. Lee, J. George, M. Mattheus +1 more
201710 citations
Semantic Scholar
Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome
D. Fitchett, Lawrence A Leiter, P. Lin, J. Pickering +7 more
2020CJC Open9 citations Open access
Semantic Scholar
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
J. Butler, G. Savarese, N. Sattar, J. Januzzi +10 more
2019Journal of the American College of Cardiology7 citations Open access
Semantic Scholar
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, D. Fitchett +6 more
2023American Journal of Preventive Cardiology6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Zinman×39
Invite
B. Zinman — researcher profile on SciRah
J. George×37
Invite
J. George — researcher profile on SciRah
C. Wanner×31
Invite
C. Wanner — researcher profile on SciRah
S. Inzucchi×24
Invite
S. Inzucchi — researcher profile on SciRah

×20

Invite

A. Ofstad — researcher profile on SciRah

Invite

S. Verma — researcher profile on SciRah

M. Mattheus×11

Invite

M. Mattheus — researcher profile on SciRah

Invite

I. Zwiener — researcher profile on SciRah

Invite

S. Hantel — researcher profile on SciRah

M. Brueckmann×9

Invite

M. Brueckmann — researcher profile on SciRah

Invite

O. Johansen — researcher profile on SciRah

Invite

J. Butler — researcher profile on SciRah